ACADIA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.21 USD | -11.21% |
|
-10.95% | -51.42% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 960M | Sales 2025 * | 1.08B | Capitalization | 2.83B |
|---|---|---|---|---|---|
| Net income 2024 * | 114M | Net income 2025 * | 207M | EV / Sales 2024 * | 2.32 x |
| Net cash position 2024 * | 603M | Net cash position 2025 * | 835M | EV / Sales 2025 * | 1.85 x |
| P/E ratio 2024 * |
27
x | P/E ratio 2025 * |
14.8
x | Employees | 598 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on ACADIA Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | -11.21% | ||
| 1 week | -10.95% | ||
| Current month | -8.98% | ||
| 1 month | -16.20% | ||
| 3 months | -42.30% | ||
| 6 months | -30.90% | ||
| Current year | -51.42% |
1 week
15.17
17.58
1 month
15.1717.90
Current year
15.1731.82
1 year
15.1733.99
3 years
12.2433.99
5 years
12.2458.72
10 years
12.2458.72
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Benir Ruano
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.73% | 0 M€ | -2.17% | - | |
| 1.24% | 0 M€ | -5.02% | ||
| 0.26% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 15.21 | -11.21% | 5,275,076 |
| 24-05-08 | 17.13 | -0.70% | 2,140,858 |
| 24-05-07 | 17.25 | +1.47% | 1,919,135 |
| 24-05-06 | 17 | -0.29% | 1,368,888 |
| 24-05-03 | 17.05 | -0.18% | 1,160,279 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
17.13
USD
Average target price
28.22
USD
Spread / Average Target
+64.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.42% | 2.83B | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
- Stock Market
- Equities
- ACAD Stock